Preferred Pharmaceuticals Initiates Class II Recall of Clindamycin Hydrochloride Capsules Due to cGMP Deviations
Preferred Pharmaceuticals, Inc. has initiated a Class II recall for 1,190 bottles of Clindamycin Hydrochloride Capsules, USP, 300mg, manufactured by Glenmark Pharmaceuticals Limited. This nationwide US recall, stemming from cGMP deviations, necessitates immediate action from procurement and regulatory teams to assess supply chain integrity and ensure patient safety. The ongoing status highlights persistent compliance challenges within the pharmaceutical sector.
Immediate Regulatory Action: Preferred Pharmaceuticals' Clindamycin Recall Due to cGMP Deviations
Preferred Pharmaceuticals, Inc., based in Anaheim, CA, United States, has initiated a Class II voluntary recall (D-0391-2025) for specific lots of Clindamycin Hydrochloride Capsules, USP, 300mg. This critical action, initiated on April 18, 2025, targets 1,190 bottles of the 30-count product, identified by NDC 68788-8685-03. The primary driver for this recall is documented deviations from current Good Manufacturing Practices (cGMP), a fundamental regulatory requirement ensuring drug quality, safety, and efficacy. The affected lots include L0224T, K1824M, K0124N, J1624V, J0824O, I2424E, I1024O, A0925F, and L2324L, all bearing an expiration date of July 31, 2026. This recall affects a broad distribution network, as the product was distributed nationwide in the US. For procurement directors, this mandates an immediate inventory review to quarantine any affected stock. Regulatory affairs heads must understand that cGMP non-compliance, even if leading to a Class II recall, signals significant quality system failures that could impact patient safety, particularly for an antibiotic like Clindamycin.
Supply Chain and Market Impact: Nationwide Distribution of Affected Clindamycin Hydrochloride Capsules
The recall of 1,190 bottles of Clindamycin Hydrochloride Capsules, USP, 300mg, distributed nationwide across the United States, presents immediate supply chain challenges for distributors, pharmacies, and healthcare providers. While Preferred Pharmaceuticals, Inc. is the recalling firm, the product was manufactured by Glenmark Pharmaceuticals Limited, highlighting the intricate multi-tiered nature of pharmaceutical supply chains. This distinction underscores that cGMP compliance responsibility extends beyond the direct vendor to the original manufacturer. A Class II classification indicates that exposure to the violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. However, for supply chain VPs, any disruption to a commonly prescribed antibiotic like Clindamycin necessitates contingency planning. Business development executives should monitor how this event impacts market dynamics for Clindamycin suppliers. Procurement teams must not only verify the recall status of their current inventory but also re-evaluate their supplier qualification processes to ensure robust oversight of both distributors and manufacturing partners, especially concerning cGMP adherence.
Navigating cGMP Compliance Risks: Implications for Pharmaceutical Procurement and Regulatory Strategy
The cGMP deviations leading to the Preferred Pharmaceuticals recall of Clindamycin Hydrochloride Capsules serve as a critical reminder for the global chemical and life sciences industry regarding the foundational importance of manufacturing quality. For regulatory affairs heads, this event underscores the FDA's continuous scrutiny of pharmaceutical manufacturing processes. The 'Ongoing' status of the recall indicates that the full scope of remediation by Preferred Pharmaceuticals and Glenmark Pharmaceuticals Limited, and any subsequent FDA actions, are yet to be finalized. This situation demands a proactive approach from companies sourcing finished drug products or active pharmaceutical ingredients (APIs). Recent parallel events, such as Essential Wellness Pharma's Progesterone Injection recall in June 2026 due to sterility assurance failures, reinforce a stringent regulatory environment. Procurement directors must enhance their due diligence, including rigorous third-party audits and comprehensive quality agreements that clearly delineate responsibilities between manufacturers and distributors. Investing in robust supplier quality management systems is paramount to mitigate the financial and reputational risks associated with cGMP non-compliance and product recalls.